Showing 4711-4720 of 5771 results for "".
- Stoke Therapeutics Presents Preclinical Data on Potential Treatment For Inherited Optic Nerve Disorderhttps://modernod.com/news/stoke-therapeutics-presents-preclinical-data-on-potential-treatment-for-inherited-optic-nerve-disorder/2477751/Stoke Therapeutics announced new preclinical data demonstrating in-vitro and in-vivo target engagement and protein upregulation in OPA1 protein-deficient cells. OPA1 protein deficiency is the primary cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorde
- Alcon to Highlight Scientific Program Showcasing Latest Innovations at Virtual ASCRShttps://modernod.com/news/alcon-to-highlight-scientific-program-showcasing-latest-innovations-at-virtual-ascrs/2477746/Alcon will present data that supports advancements in cataract surgery during the virtual American Society of Cataract and Refractive Surgery (ASCRS) 2020 annual meeting, taking place May 16-17. The company will also host a virtual exhibit booth that will provide information on its latest product
- AbbVie Completes Acquisition of Allerganhttps://modernod.com/news/abbvie-completes-acquisition-of-allergan/2477739/AbbVie announced that it has completed its acquisition of Allergan after receiving regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. “We are pleased to reach this important milestone for the company, its em
- Dyno Therapeutics Collaborates With Novartis to Develop Improved Gene Therapies With AAV Vectors Based on AI Technologyhttps://modernod.com/news/dyno-therapeutics-collaborates-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/2477740/Dyno Therapeutics announced a collaboration with Novartis to develop improved adeno-associated virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. Financial terms of the deal were not disclosed. The partnership will allow the p
- FDA Approves Quidel’s Sofia 2, First Antigen Test to Help in the Rapid Detection of COVID-19https://modernod.com/news/quidel-receives-emergency-authorization-for-rapid-antigen-covid-19-diagnostic-assay/2477735/Quidel, which makes diagnostic tests for a variety of conditions including acute conjunctivitis and dry eye disease, announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- Doximity Enters Telemedicine With Launch of Dialer Videohttps://modernod.com/news/doximity-enters-telemedicine-with-launch-of-dialer-video/2477732/Doximity announced the launch of Doximity Dialer Video, the company’s first telemedicine offering. With one click, Doximity Dialer Video lets doctors video call their patients, in an encrypted environment that complies with HIPAA privacy regulations. The new tool works with a doctor’s personal iO
- jCyte Enters Into Ex-US Licensing and Commercialization Agreement for jCell Therapy With Santenhttps://modernod.com/news/jcyte-enters-into-ex-us-licensing-and-commercialization-agreement-for-jcell-therapy-with-santen/2477727/jCyte Inc. announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the United States, in regions including Europe, Asia, and Japan. Under the terms of the licensing agreement, jC
- Sight Sciences Introduces the Next-Generation Omni Surgical System for Microinvasive Glaucoma Surgeryhttps://modernod.com/news/sight-sciences-introduces-the-next-generation-omni-surgical-system-for-microinvasive-glaucoma-surgery/2477720/Sight Sciences announced the launch of its next-generation Omni Surgical System for microinvasive glaucoma surgery (MIGS) procedures. The Omni Surgical System combines two distinct angle procedures—ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS
- Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-to-present-results-from-its-phase-2-trial-of-ocs-01-for-inflammation-and-pain-following-cataract-surgery/2477721/Oculis announces that it will present results from its phase 2 (SKYGGN) clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, at the American Society of Cataract and Refractive Surgery (ASCRS) annual